ストックスクリーナーアプリを入手
27.22
0.11%
0.03
アフターアワーズ：
27.23
0.01
+0.04%
前日終値:
$27.19
開ける：
$27.205
24時間の取引高:
21.88M
Relative Volume:
0.50
時価総額：
$154.84B
収益：
$62.58B
当期純損益:
$7.79B
株価収益率:
20.09
EPS:
1.3551
ネットキャッシュフロー:
$9.08B
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+2.29%
6か月 パフォーマンス:
+12.34%
1年 パフォーマンス:
+23.50%
1日の値動き範囲:
$27.15
$27.48
1週間の範囲:
$26.68
$27.57
52週間の値動き範囲:
$21.87
$28.75
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.22 | 154.67B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
903.99 | 808.52B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.54 | 574.86B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.99 | 368.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.47 | 312.04B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
149.73 | 290.19B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer (PFE) CEO Albert Bourla receives 911 phantom stock units as deferred pay - Stock Titan
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Pfizer-Backed EV-209 Trial Targets Bladder Preservation in High-Need Cancer Segment - TipRanks
Pfizer stock price forecast: sideways trading expected as PFE consolidates above key supports - Traders Union
Here Are Thursday’s Top Wall Street Analyst Research Calls: Autoliv, CoreWeave, Corning, Dicks Sporting Goods, Federated Hermes, Gitlab, PayPal, Pfizer, Okta, and More - 24/7 Wall St.
Lbp Am Sa Has $25.32 Million Stake in Pfizer Inc. $PFE - MarketBeat
KBC Group NV Purchases 706,426 Shares of Pfizer Inc. $PFE - MarketBeat
CICC Initiates Pfizer at Outperform With $33 Price Target - marketscreener.com
DND Pharmatech Wins KRW1.83 Billion Anti-Obesity Drug Formulation Contract from Pfizer; Shares Rise 3% - marketscreener.com
New weight loss drug by Pfizer shows promising results in trial - AOL.com
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings - Yahoo Finance
How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed - Pfizer
Pfizer Inc. stock (US7170811035): Is its wide moat strong enough to unlock new upside? - AD HOC NEWS
UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target - Insider Monkey
Pfizer is Latest Target of FDA's Crackdown on Direct-to-Consumer, Social Media Ads - Law.com
BRAF Mutated Non-small Cell Lung Cancer Market: Rapid Increment Driven by Innovation by 2036 – DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart
Pfizer Exec on Building Data, Process Foundation for AI - WSJ
Former Pfizer exec estimates 20,000 to 60,000 deaths from COVID shot in Germany - Todayville
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results - qz.com
Earnings Preview: What to Expect From Pfizer’s Report - Barchart.com
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE) - The Globe and Mail
Wells Fargo Releases a Hold Rating on Pfizer (PFE) - The Globe and Mail
Pfizer Inc. stock (US7170811035): Is its post-COVID pivot strong enough to unlock new upside? - AD HOC NEWS
Pfizer, DoHDA talks stall as PBS listing times blow out to almost two years - Health Services Daily
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Pfizer (NYSE:PFE) Trading Up 1.5% on Analyst Upgrade - MarketBeat
Pfizer Options Spot-On: On April 13th, 179.18K Contracts Were Traded, With 2.52 Million Open Interest - Moomoo
UBS Raises Price Target on Pfizer to $27 From $25, Maintains Neutral Rating - marketscreener.com
FDA flags Facebook ads for Pfizer’s cancer drug as misleading - Medical Marketing and Media
UBS Initiates Pfizer(PFE.US) With Hold Rating, Announces Target Price $27 - Moomoo
Guggenheim reiterates Buy on Pfizer stock ahead of earnings - Investing.com
Guggenheim reiterates Buy on Pfizer stock ahead of earnings By Investing.com - Investing.com Australia
Guggenheim Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Trellus Health signs renewal of licensing deal with Pfizer - London South East
BMO Capital Adjusts Price Target on Pfizer to $34 From $30, Maintains Outperform Rating - marketscreener.com
Trellus Health shares jump 39% on Pfizer deal renewal - Proactive Investors
Healthcare Stocks: J&J & Pfizer 2026 Outlook Amid Tech ShiftsNews and Statistics - IndexBox
BofA Lowers its Price Target on Pfizer (PFE) to $26 from $27 - Yahoo Finance
Pfizer Inc. Trade Ideas — BSESOF:PFE - TradingView — Track All Markets
Better Buy Right Now: Johnson & Johnson Vs. Pfizer - The Globe and Mail
Pfizer Inc (PFE) Stock Price Quote Today & Current Price Chart - Capital.com
Pfizer’s China Biotech Push Adds New Angle To PFE Valuation Story - Yahoo Finance
Pfizer Options Spot-On: On April 10th, 104.09K Contracts Were Traded, With 2.48 Million Open Interest - Moomoo
Pfizer (PFE) Faces FDA Scrutiny Over Misleading Adcetris Ads - GuruFocus
How Investors Are Reacting To Pfizer (PFE) As RBC Flags Pressure On Key Drug Franchise - simplywall.st
Pfizer (NYSE: PFE) SVP discloses stock and appreciation right holdings - Stock Titan
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer? - The Globe and Mail
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $28 - Moomoo
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30 - Moomoo
PFIZER INC : Gets a Neutral rating from JP Morgan - marketscreener.com
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.29%
大文字化:
|
ボリューム (24 時間):